Podcasts · Science

Talking Points

TCTMD

213 episodes

A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b

Episodes page 1 of 5

  1. The BHF PROTECT-TAVI Trial

    · 5:42

    Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.

  2. The FAME 3 Trial

    · 9:02

    William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.

  3. The TRILUMINATE Pivotal Trial

    · 8:04

    Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.

  4. The PRAGUE-25 Study

    · 7:57

    Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.

  5. The BETAMI-DANBLOCK Trial

    · 8:38

    How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.

  6. New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI

    · 1 h 33 min

    In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.

  7. The PROCTOR Trial

    · 8:35

    Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.

  8. The SELUTION DeNovo Trial

    · 5:08

    Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.

  9. The VESALIUS-CV Trial

    · 7:21

    Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.

  10. The META-AF Trial

    · 4:42

    Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.

  11. Evolution of Pharmacotherapy in STEMI

    · 8:17

    How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.

  12. The CorCMR Trial

    · 5:50

    Colin Berry and C. Michael Gibson discuss whether stress CMR imaging is helpful in patients with angina and no obstructive CAD.

  13. The TUXEDO-2 Trial

    · 3:56

    Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.

  14. The FLOW Trial

    · 5:33

    C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.

  15. The 2024 ESC CCS Guidelines

    · 16 min

    Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.

  16. The My Heart Your Heart Trial

    · 6:26

    Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.

  17. The FAVOR III Europe Trial

    · 14 min

    Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.

  18. The FLOW Trial

    · 5:33

    C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.

  19. STORM-PE TRIAL

    · 14 min

    James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).

  20. The EARLY TAVR and TAVR UNLOAD Trials

    · 15 min

    For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.

  21. The EPIC-CAD Trial

    · 14 min

    Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.

  22. The ECLIPSE Trial

    · 7:38

    Ajay Kirtane and C. Michael Gibson discuss how orbital atherectomy compares with balloon angioplasty for severely calcified coronary arteries before DES implantation.

  23. The CLEAR SYNERGY (OASIS 9) Trial

    · 7:45

    Does long-term colchicine benefit patients after acute MI? C. Michael Gibson and Sanjit Jolly discuss. 097245

  24. The NOTION-3 Trial

    · 17 min

    Mamas Mamas talks to Jacob Thomsen Lønborg about how PCI affects outcomes for patients with stable CAD undergoing TAVI.

  25. TMVR in the Heart Failure Paradigm

    · 14 min

    Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by…

  26. The ABYSS Trial

    · 6:02

    Johanne Silvain, Gilles Montalescot, and C. Michael Gibson discuss the effects of beta-blocker interruption in post-MI patients.

  27. Patient Selection and Treatment Goals

    · 15 min

    Patient selection is important for transcatheter interventions and impacts result success. This discussion focuses on defining what treatment goals should be, limitations of current interventions, and identifying…

  28. Women's Health Study: Biomarkers

    · 9:51

    Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b

  29. Echocardiography and Quality Data

    · 22 min

    Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval…

  30. Insights on Intrepid 2-Yr Mitral TF EFS

    · 16 min

    The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the…

  31. New ESC Guidelines for AF

    · 20 min

    Renate Schnabel, Ruben Casado Arroyo, and Mamas Mamas discuss the atrial fibrillation recommendations unveiled at ESC Congress 2024.

  32. The STEEER-AF Trial

    · 5:57

    Dipak Kotecha talks to C. Michael Gibson about whether educating healthcare providers on rhythm-control therapy affects guideline adherence and stroke outcomes.

  33. The EPIC-CAD Trial

    · 12 min

    Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.

  34. Acute Coronary Care in Ethiopia

    · 12 min

    Mamas Mamas talks to Tesfaye Telila about the landscape of acute coronary care in Ethiopa, where just a few dozen cardiologists contend with a population of 120 million people.

  35. The POPular PAUSE TAVI Trial

    · 4:47

    Should we stop anticoagulation therapy before TAVI in patients with aortic stenosis? Dirk-Jan van Ginkel and C. Michael Gibson discuss.

  36. The SENIOR-RITA Trial

    · 10 min

    Vijay Kunadian talks to C. Michael Gibson about using an invasive or conservative strategy for older patients with NSTEMI.

  37. The REDUCE-AMI Trial

    · 13 min

    Troels Yndigegn, Sripal Bangalore, and Mamas Mamas discuss whether beta-blockers still benefit patients with acute MI and preserved ejection fraction.

  38. The EARTH-STEMI Trial

    · 6:16

    Gianluca Campo and C. Michael Gibson compare complete versus culprit-only revascularization in older STEMI patients.

  39. The SCOFF Trial

    · 7:23

    David Ferreira talks to C. Michael Gibson about the latest data showing patients don't need to fast ahead of cardiac catheterization.

  40. The RESHAPE-HF2 and MATTERHORN Trials

    · 17 min

    Mamas Mamas, Stefan Anker, and Volker Rudolph talk about their studies of MitraClip for functional MR in patients with heart failure.

  41. The EMPACT-MI Trial

    · 6:23

    Javed Butler and C. Michael Gibson discuss the trial testing early empagliflozin after acute MI.

  42. The PROACT Trial

    · 4:24

    Talking with C. Michael Gibson, David Austin reviews the phase III trial of enalapril for anthracycline-induced cardiotoxicity in lymphoma and breast cancer patients.

  43. The ORBITA-COSMIC Trial

    · 13 min

    Rasha Al-Lamee and Michael Foley sit down with Mamas Mamas to discuss data on an implantable coronary sinus reducer that can ease symptoms in patients with refractory angina.

  44. The REVIVED-BCIS2 Randomized Trial

    · 6:16

    Looking at the REVIVED-BCIS2 results, Divaka Perera and C. Michael Gibson discuss the relationship between myocardial viability, PCI, and outcomes.

  45. Ketogenic Diet and Cardiovascular Risk

    · 6:26

    Iulia Iatan talks to C. Michael Gibson about how a low-carbohydrate, high-protein diet can increase plasma lipid levels and cardiovascular risk.

  46. The CLEAR Outcomes Trial

    · 7:03

    Steven Nissen and C. Michael Gibson discuss using bempedoic acid to reduce MACE in statin-intolerant patients with high cardiovascular risk.

  47. Inflammatory Risk in Statin-Treated Patients

    · 12 min

    Pooling data from the PROMINENT, REDUCE-IT, and STRENGTH trials, Paul Ridker and C. Michael Gibson discuss the residual inflammatory risks for patients treated with statins.

  48. The BUDAPEST CRT Upgrade Trial

    · 13 min

    Béla Merkely and C. Michael Gibson discuss the results of a CRT-D upgrade versus ICD alone for HFrEF patients with right ventricular pacing.

  49. The HEART-FID Trial

    · 4:58

    Robert Mentz and C. Michael Gibson discuss the latest trial to address whether iron supplementation, this time with ferric carboxymaltose, improves outcomes for patients with HF and iron deficiency.

  50. The FIRE Study

    · 7:59

    Simone Biscaglia and C. Michael Gibson discuss physiology-guided complete revascularization versus culprit-only PCI for elderly patients with acute MI.

Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them. Explicit shows are for adult profiles only, and children’s profiles hear only children’s shows. More about this list.